This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Syneron Receives FDA Clearance For "me" Home-Use Hair Removal System

Stocks in this article: ELOS

YOKNEAM, Israel, Oct. 18, 2012 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the leading global aesthetic device company, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the me Home-Use Hair Removal System to consumers (OTC). This marks the first home-use product featuring Syneron's proprietary elos technology to be cleared by the FDA. Syneron expects its subsidiary, Syneron Beauty, will initiate the U.S. commercial launch of the me system through prestige retailers and directly to consumers during the first quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20120528/535447 )

The me system is the first and only FDA cleared consumer hair removal technology that is approved for all skin tones. The system's revolutionary patented elos technology combines the power of Intense Pulse Light (IPL) and Radio Frequency (RF) energies, allowing it to achieve superior results with lower overall optical energy output and the highest level of safety and comfort. It is CE Marked, approved by Health Canada, and has been commercially available in several European markets since 2011. More information on the me system is available at www.memyelos.com.

Louis Scafuri, Chief Executive Officer of Syneron Medical, said, "Gaining FDA clearance for the me home-use hair removal system is a significant milestone for Syneron. It represents the first home-use application of Syneron's proprietary elos technology in the U.S., where it is already broadly used in Syneron's professional aesthetic products by plastic surgeons, dermatologists and other professional providers."

Fabian Tenenbaum, Chief Executive Officer of Syneron Beauty, said: "The me system is the only consumer hair removal technology that is approved for all skin tones, increasing the addressable consumer market and underscoring the technological advantages of our proprietary elos technology for home-use aesthetic products. The me system has been well received in Europe and we are confident that consumers in the U.S. will be similarly attracted to its strong efficacy and unmatched comfort and safety profile."

Jerome M. Garden, M.D., Department of Dermatology, Northwestern University, stated, "The Company conducted a 100-patient clinical study, covering all skin colors, at four leading dermatologist sites in the U.S., using the me hair removal instrument. The data from the study supports efficacy across all skin tones and confirmed a significant safety profile."

About Syneron Beauty

Syneron Beauty is a pioneer in the design, development and distribution of sophisticated consumer home-use aesthetic devices and products. The Company's products are based on clinically proven technologies derived from the professional aesthetic device market, enabling patients to achieve professional-like results in an at-home setting. Syneron Beauty currently markets the Tandaâ„¢ family of home-use light therapy and teeth whitening products and the me home-use hair removal system. The Company also has a home-use partnership with Procter & Gamble and several other new products in development. Syneron Beauty is based in New York, NY and is a wholly owned subsidiary of Syneron Medical Ltd. (NASDAQ: ELOS).



1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs